Unlocking Diagnostic Clarity to Accelerate Market Ready Strategy
The challenge
Ahead of launch, a global pharma company assumed biomarker familiarity equated to test readiness. Assessment across Accuracy, Awareness and Adoption within the Diaceutics 6A™ Framework revealed significant gaps in this assumed readiness. There was limited visibility into real-world testing behaviors, unclear barriers to clinician adoption, varied workflows across markets and no unified diagnostic strategy to guide execution.
Our Approach
Diaceutics delivered a structured, multi-market program that replaced assumptions with evidence and built a clear, market‑ready diagnostic roadmap.
- Delivered multi‑market diagnostic landscapes that revealed real‑world levels of Accuracy, Awareness, and Adoption, replacing assumptions with a clear view of diagnostic realities.
- Converted insight into a global diagnostic strategy and launch playbook, aligning internal teams behind unified priorities, timelines, and implementation steps.
- Built country‑specific diagnostic strategies, addressing variations in in-market behaviors, workflows, testing platforms and clinician decision points to ensure global alignment with local actionability.
- Delivered lab segmentation analyses, enabling precise prioritization of laboratories with the highest potential to influence clinical adoption.
- Equipped field teams with messaging and education tools, strengthening lab awareness and supporting diagnostic adoption in a new indication.
- Accelerated internal capability building, strengthening cross‑functional understanding of testing pathways and precision medicine requirements.
The Impact
Diaceutics advanced the client from assumption‑based planning to confident, diagnostic‑ready execution.
- Revealed diagnostic blind spots that had not been previously identified, strengthening launch preparedness.
- Delivered a full diagnostic strategy in under 1 year, accelerating commercial readiness in a complex disease landscape.
- Enabled targeted engagement with high‑impact labs, supporting day‑one readiness for diagnostic access and lab adoption.
- Mitigated launch risk early by exposing misalignments between real‑world testing practices and therapy needs.
The Impact
Diaceutics advanced the client from assumption‑based planning to confident, diagnostic‑ready execution.
- Revealed diagnostic blind spots that had not been previously identified, strengthening launch preparedness.
- Delivered a full diagnostic strategy in under 1 year, accelerating commercial readiness in a complex disease landscape.
- Enabled targeted engagement with high‑impact labs, supporting day‑one readiness for diagnostic access and lab adoption.
- Mitigated launch risk early by exposing misalignments between real‑world testing practices and therapy needs.
Impact statement for highlighting on case study:
“Day‑one lab readiness strengthened diagnostic readiness and supported timely adoption.”
“A fully defined diagnostic strategy delivered in under a year enabled confident launch execution”
Navigate complexity, accelerate adoption, and drive sustained growth.
Connect with us today to unlock your therapy's full potential.
You might also be interested in?
Rethinking Drug Commercialization: Navigating a Shifting Biotech Investment Landscape
Explore strategies for biotech commercialization amid evolving investment landscapes, focusing on precision and rare disease therapies. Join industry experts in navigating funding challenges and enhancing patient outcomes.